Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants

Toxicology and Applied Pharmacology

Volumn 198, Issue 2, 2004, Pages 164-183

  Ginsberg, Gary ^a   Hattis, Dale ^b   Sonawane, Babasaheb ^c  

^a CDC   (United States)

^b CLARK UNIVERSITY   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Children; Metabolism; Pharmacokinetics; Risk assessment

Indexed keywords

ALCOHOL DEHYDROGENASE; CAFFEINE; CYTOCHROME P450; EPOXIDE; HYDROLASE; THEOPHYLLINE; TOXIC SUBSTANCE;

ABSORPTION; AEROSOL; AGE DISTRIBUTION; CALIBRATION; CHEMICAL REACTION; DEVELOPMENTAL STAGE; ENVIRONMENTAL EXPOSURE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; NONHUMAN; POSTNATAL DEVELOPMENT; REVIEW; RISK ASSESSMENT; TOXICITY TESTING;

EID: 3242706911     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2003.10.010     Document Type: Article

References (175)

1. Abraham S.K., Singh S.P., Kesavan P.C. Buthionine sulfoximine mediated enhancement of gamma-radiation induced mutation frequency in Drosophila melanogaster. Mutat. Res. 301:1993;255-259
2. Alcorn J., McNamara P.J. Ontogeny of hepatic and renal systemic clearance pathways in infants: Part II. Clin. Pharmacokinet. 41:2002;1077-1094
3. Aldridge A., Aranda J.V., Neims A.H. Caffeine metabolism in the newborn. Clin. Pharmacol. Ther. 25:1979;447-453
4. Amaral S.L., Maier K.G., Schippers D.N., Roman R.J., Greene A.S. CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am. J. Physiol.: Heart Circ. Physiol. 284:2003;H1528-H1535
5. Andersen M.E., Clewell H.J., Gargas M.L., Smith F.A., Reitz R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87:1987;185-205
6. Anderson L.M., Ruskie S., Carter J., Pittinger S., Kovatch R.M., Riggs C.W. Fetal mouse susceptibility to transplacental carcinogenesis: differential influence of Ah receptor phenotype on effects of 3-methylcholanthrene, 12-dimethylbenz[a]anthracene, and benzo[a]pyrene. Pharmacogenetics. 5:1995;364-372
7. Anderson B.J., McKee A.D., Holford H.G. Size, myths, and the clinical pharmacokinetics of analgesia in pediatric patients. Clin. Pharmacokinet. 33:1997;313-327
8. Aranda J.V., Cook C.E., Gorman W., Collinge J.M., Loughnan P.M., Outerbridge E.W., Aldridge P.T.A., Neims A.H. Pharmacokinetic profile of caffeine in the premature newborn with apnea. J. Pediatr. 94:1979;663-668
9. Aoyama T., Yamano S., Guzelian P.S., Gelboin H.V., Gonzalez F.J. Five of twelve forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc. Natl. Acad. Sci. 87:1990;4790-4793
10. ATSDR Toxicological Profile for Lead. Agency for Toxic Substances and Disease Registry. 1999;U.S. Dept. Health and Human Services, Atlanta, GA
11. Aylward L.L., Hays S.M., Lakind J.S., Ryan J.J. Partitioning of persistent lipophilic compounds, including dioxins, between human milk lipid and blood lipid: an initial assessment. J. Toxicol. Environ. Health, Part A. 66:2003;1-5
12. Barker N., Hadgraft J., Rutter N. Skin permeability in the newborn. J. Invest. Dermatol. 88:1987;409-411
13. Barrett D.A., Rutter N. Percutaneous lignocaine absorption in newborn infants. Arch. Dis. Child. 71:1994;F122-F124
14. Barrett D.A., Rutter N., Davis S.S. An in vitro study of diamorphine permeation through premature human neonatal skin. Pharmacol. Res. 10:1993;583-587
15. Bennett W.D., Zeman K.L. Deposition of fine particles in children spontaneously breathing at rest. Inhalation Toxicol. 10:1998;831-842
16. Besunder J.B., Reed M.D., Blumer J.L. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I). Clin. Pharmacokinet. 14:1988;189-216
17. Blanco J.G., Harrison P.L., Evans W.E., Relling M.V. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab. Dispos. 28:2000;379-382
18. Bois F.Y., Zeise L., Tozer T.N. Precision and sensitivity of pharmacokinetic models of cancer risk assessment: tetrachloroethylene in mice, rats, and humans. Toxicol. Appl. Pharmacol. 102:1990;300-315
19. Bonati M., Latini R., Marra G., Assael B.M., Parini R. Theophylline metabolism during the first month of life and development. Pediatr. Res. 15:1981;304-308
20. Bonina F.P., Montenegro L., Micali G., West D.P., Palicharla P., Koch R.L. In vitro percutaneous absorption evaluation of phenobarbital through hairless mouse, adult and premature human skin. Int. J. Pharmacol. 98:1993;93-99
21. Bortollotti A., Corada M., Barzago M.M., Celardo A., Guaitani A., Bonati M. Pharmacokinetics of theophylline in the newborn. Drug Metab. Dispos. 19:1991;430-435
22. Boucher F.D., Modlin J.F., Weller S., Ruff A., Mirochnick M., Pelton S. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J. Pediatr. 122:1993;137-144
23. Bowers T.S., Cohen J.T. Blood lead slope factor models for adults: comparisons of observations and predictions. Environ. Health Perspect. 106(Suppl. 6):1998;1569-1576
24. Bruckner J.V. Differences in sensitivity of children and adults in chemical toxicity. Regul. Toxicol. Pharmacol. 31:2000;280-285
25. Bruning T., Lammert M., Kempkes M., Their R., Golka K., Bolt H.M. Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch. Toxicol. 71:1997;596-599
26. Buratti F.M., Volpe M.T., Fabrizi L., Meneguz A., Vittozzi L., Testai E. Kinetic parameters of OPT pesticide desulfuration by c-DNA expressed human CYPs. Environ. Toxicol. Pharmacol. 11:2002;181-190
27. Buratti F.M., Volpe M.T., Meneguz A., Vittozzi L., Testai E. CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. Toxicol. Appl. Pharmacol. 186:2003;143-154
28. Byczkowski J.Z., Kinkead E.R., Leahy H.F., Randall G.M., Fisher J.W. Computer simulation of the lactational transfer of tetrachloroethylene in rats using a physiologically-based model. Toxicol. Appl. Pharmacol. 125:1994;228-236
29. Carrier O., Pons G., Rey E., Richard M.-O., Moran C., Badoual J., Olive G. Maturation of caffeine metabolic pathways in infancy. Clin. Pharmacol. Ther. 44:1988;145-151
30. Cartwright R.A., Rodgers H.J., Barham-Hall D. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 1982;842-846
31. Cascorbi I., Krakoulis N., Brockmoller J., Maurer A., Sperling K., Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet. 57:1995;581-592
32. Catassi C., Bonucci A., Coppa G.V., Carlucci A., Giorgi P.L. Intestinal permeability changes during the first month: effect of natural versus artificial feeding. Pediatr. Gastroenterol. Nutr. 21:1995;383-486
33. Chantry C.J., Rodriguez J.L., Febo I., Diaz C., Rodriguez-Orengo J.F. Plasma glutathione concentrations in non-infected infants born from HIV-infected mothers: developmental profile. P. R. Health Sci. J. 18:1999;267-272
34. Cheng W.S.C., Murphy T.L., Smith M.T., Cooksley W.G.E., Halliday J.H.W., Powell L.W. Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin. Pharmacol. Ther. 47:1990;516-524
35. Clahsen P.C., Moison R.M., Holtzer C.A., Berger H.M. Recycling of glutathione during oxidative stress in erythrocytes of the newborn. Pediatr. Res. 32:1992;399-402
36. Clewell H.J., Gearhart J.M., Gentry P.R., Covington T.R., VanLandingham C.B., Crump K.S., Shipp A.M. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal. 19:1999;547-558
37. Clewell H.J., Teeguarden J., McDonald T., Sarangapani R., Lawrence G., Covington T., Gentry R., Shipp A. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 32:2002;329-389
38. Cresteil T. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit. Contam. 15:1998;45-51. (Suppl.)
39. Cowart L.A., Wei S., Hsu M.-H., Johnson E.F., Krishna M.U., Falck J.R., Capdevila J.H. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J. Biol. Chem. 277:2002;35105-35112
40. Dahl A.R., Schlesinger R.B., Heck H.D'A., Medinsky M., Lucier G. Comparative dosimetry of inhaled materials: differences among animal species and extrapolation to man. Fundam. Appl. Toxicol. 16:1991;1-13
41. Daley-Yates P.T., Tournant J., Kunka R.L. Comparison of the systemic availability of fluticasone proprionate in healthy volunteers and patients with asthma. Clin. Pharmacokinet. 39:2000;39-45
42. Dewan A., Chattopadhyay P., Kulkarni P.K. N-acetyltransferase activity - A susceptibility factor in human bladder carcinogenesis. Indian J. Cancer. 32:1995;15-19
43. de Wildt S.N., Kearns G.L., Leeder J.S., van den Anker J.N. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin. Pharmacokinet. 36:1999;439-452
44. Diem K., Lentner C. Documenta Geigy: Scientific Tables. 7th ed.:1970;Geigy Pharmaceuticals, Ardsley, NY
45. Dorne J.L.C.M., Walton K., Renwick A.G. Uncertainty factors for chemical risk assessment: human variability in the pharmacokinetics of CYP1A2 probe substrates. Food Chem. Toxicol. 39:2001;681-696
46. Eaton D.L., Gallagher E.P., Bammler T.K., Kunze K.L. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics. 5:1995;259-274
47. Eichelbaum M., Ekbom K., Bertilsson L., Ringberger V.A., Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur. J. Clin. Pharmacol. 8:1975;337-341
48. Eichelbaum M., Tomson T., Tybring G., Bertilsson L. Carbamazepine metabolism in man induction and pharmacogenetic aspects. Clin. Pharmacokinet. 10:1985;80-90
49. Evans D.A.P., Eze L.C., Whibley E.J. The association of the slow acetylator phenotype with bladder cancer. J. Med. Genet. 20:1983;330-333
50. Filiadis I.F., Georgiou I., Alamanos Y., Kranas V., Giannakopoulos X., Lolis D. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J. Urol. 161:1999;1672-1675
51. Fiserova-Bergerova V. Extrapolation of physiological parameters for physiologically based simulation models. Toxicol. Lett. 79:1995;77-86
52. Garbis-Berkvens J.M., Peters P.W. Comparative morphology and physiology of embryonic and fetal membranes. Nau H., Scott J. Pharmacokinetics in Teratogenesis. vol. 1:1987;14-44 CRC Press, Boca Raton, FL
53. Gentry R., Teeguarden J., Sarangapani R., Covington T., Lawrence G., MacDonald T., Shipp A., Clewell H. Evaluation of the potential impact of age and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 66:2002;1-S. (Abstract # 251)
54. Gibbs J.P., Murray G., Risler L., Chien J.Y., Dev R., Slattery J.T. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high dose busulfan. Cancer Res. 57:1997;5509-5516
55. Ginsberg G., Hattis D., Sonawane B., Russ A., Banati P., Kozlak M., Smolenski S., Goble R. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 66:2002;185-200
56. Ginsberg G., Hattis D., Russ A., Sonawane B. Physiologically-based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J. Toxicol. Env. Health, Part A. 67:2004;297-329
57. Gow P.J., Ghabrial H., Smallwood R.A., Morgan D.J., Ching M.S. Neonatal hepatic drug elimination. Pharmacol. Toxicol. 88:2001;3-15
58. Grygiel J.J., Birkett D.J. Effect of age on patterns of theophylline metabolism. Clin. Pharmacol. Ther. 28:1980;456-462
59. Guengerich F., Kim D., Iwasaki M. Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4:1991;168-179
60. Gut I., Nedelcheva V., Soucek P., Stopka P., Tichavsak B. Cytochromes P450 in benzene metabolism and involvement of their metabolites and reactive oxygen species in toxicity. Environ. Health Perspect. 104(Suppl. 6):1996;1211-1218
61. Ha H.R., Chen J., Freiburghaus A.U., Follath F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br. J. Clin. Pharmacol. 39:1995;321-326
62. Ha H.R., Chen J., Krahenbuhl S., Follath F. Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur. J. Clin. Pharmacol. 49:1996;309-315
63. Haddad S., Restieri C., Krishnan K. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J. Toxicol. Environ. Health, Part A. 64:2001;453-464
64. Haines J.W., Naylor G.P.L., Pottinger H., Harrison J.D. Gastrointestinal absorption and retention of polonium in adult and newborn rats and guinea pigs. Int. J. Radiat. Biol. 64:1993;127-132
65. Hakkola J., Tanaka E., Pelkonen O. Developmental expression of cytochrome P-450 enzymes in human liver. Pharmacol. Toxicol. 82:1998;209-217
66. Harpin V.A., Rutter N. Barrier properties of the newborn infant's skin. J. Pediatr. 102:1983;419-425
67. Hashimoto H., Nakagawa T., Yokoi T., Sawada M., Itoh S., Kamataki T. Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins. Cancer Res. 55:1995;787-791
68. Hattis D., White P., Koch P. Uncertainties in pharmacokinetic modeling for perchloroethylene: II. Comparison of model predictions with data for a variety of different parameters. Risk Anal. 13:1993;599-610
69. Hattis D., Ginsberg G., Sonawane B., Smolenski S., Russ A., Kozlak M., Goble R. Differences in pharmacokinetics between children and adults: II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal. 23:2003;117-142
70. Hines R.N., McCarver D.G. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J. Pharmacol. Exp. Ther. 300:2002;355-360
71. Hoffman H. Absorption of drugs and other xenobiotics during development in experimental animals. Pharmacol. Ther. 16:1982;247-260
72. Holliday M.A. Metabolic rate and organ size during growth from infancy to maturity and during late gestation and early infancy. Pediatrics. 47:1971;169-179
73. Idanpaan-Heikkila J., Jouppila P., Akerblom H.K., Isoaho R., Kauppila E., Koivisto M. Elimination and metabolic effects of ethanol in mother, fetus, and newborn infant. Am. J. Obstet. Gynecol. 112:1972;387-393
74. Illsley N.P., Hall S., Penfold P., Stacey T.E. Diffusional permeability of the human placenta. Contrib. Gynecol. Obstet. 13:1985;92-97
75. Inatomi H., Katoh T., Kawamoto T.L., Matsumoto T. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int. J. Urol. 6:1999;446-454
76. Jain A., Mehta T., Auld P., Rodrigues J., Ward R., Schwartz M.M. Glutathione metabolism in newborns: evidence for glutathione deficiency in plasma, bronchoalveolar lavage fluid, and lymphocytes in prematures. Pediatr. Pulmonol. 20:1995;160-166
77. Jarabek A.M., Menache M.G., Overton J.H., Dourson M.L., Miller F.J. Inhalation reference dose (RfDi); an application of interspecies dosimetry modeling for risk assessment of insoluble particles. Health Phys. 57(Suppl. 1):1989;177-183
78. Jerina D.M. Metabolism of aromatic hydrocarbons by the cytochrome P-450 system and epoxide hydrolase. Drug Metab. Dispos. 11:1983;1-4
79. Johanson G., Filser J.G. Experimental data from closed chamber gas uptake studies in rodents suggest lower uptake rate of chemical than calculated from literature values on alveolar ventilation. Arch. Toxicol. 66:1992;291-295
80. Johnson E.F., Hsu M.H., Savas U., Griffin K.J. Regulation of P450 expression by peroxisome proliferator activated receptors. Toxicology. 27:2002;203-206
81. Jonsson F., Johanson G. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology. 157:2001;177-193
82. Josyula S., Lu L.J., Salazar J.J., Nerurkar P.V., Jones A.B., Grady J.J., Snyderwine E.G., Anderson L.M. DNA adducts of 2-amino-3-methylimidazo[4,5-f] quinoline (IQ) in fetal tissues of patas monkeys after transplacental exposure. Toxicol. Appl. Pharmacol. 166:2000;151-160
83. Kaide J., Wang M.H., Wang J.S., Zhang F., Gopal V.R., Falck J.R., Nasjletti A., Laniado-Schwartzman M. Transfection of CYP4A1 cDNA increases vascular reactivity in renal interlobar arteries. Am. J. Physiol.: Renal, Physiol. 284:2003;F51-F56
84. Kakiuchi Y., Kohda Y., Miyabe M., Momose Y. Effect of plasma alpha1-acid glycoprotein concentration on the accumulation of lidocaine metabolites during continuous epidural anaesthesia in infants and children. Int. J. Clin. Pharmacol. Ther. 37:1999;493-498
85. Kearns G.L., Reed M.D. Clinical pharmacokinetics in infants and children. A reappraisal. Clin. Pharmacokinet. 17(Suppl. 1):1989;29-67
86. Kedderis G.L. Extrapolation of in vitro enzyme induction data to humans in vivo. Chem.-Biol. Interact. 107:1997;109-121
87. Kitada M., Taneda M., Ohi H., Komori M., Itahashi K., Nagao M., Kamataki T. Mutagenic activation of aflatoxin B1 by P-450 HFLa in human fetal livers. Mutat. Res. 227:1989;53-58
88. Kitada M., Taneda M., Ohta K., Nagashima K., Itahashi K., Kamataki T. Metabolic activation of aflatoxin B1 and 2-amino-3-methylimidazo(4,5-f)- quinoline by human adult and fetal livers. Cancer Res. 50:1990;2641-2645
89. Korinthenberg R., Haug C., Hannak D. The metabolism of carbamazepine to CBZ-10-11-epoxide in children from the newborn age to adolescence. Neuropediatrics. 25:1994;214-216
90. Kostial K., Kello D., Jugo S., Rabar I., Maljkovic T. Influence of age on metal metabolism and toxicity. Environ. Health Perspect. 25:1978;81-86
91. Kraus D.M., Fischer J.H., Reitz S.J., Kecskes S.A., Yeh T.F., McCulloch K.M., Tung E.C., Cwik M.J. Alterations in theophylline metabolism during the first year of life. Clin. Pharmacol. Ther. 54:1993;351-359
92. Krishnan K., Andersen M.E. Physiological pharmacokinetic models in the risk assessment of developmental neurotoxicants. Slikker W., Chang L. Handbook of Developmental Neurotoxicity. 1998;709-725 Academic Press, New York
93. Kreuzer P., Csanady Gy.A., Baur C., Kessler W., Papke O., Greim H., Filser J.G. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and congeners in infants. A toxicokinetic model of human lifetime body burden by TCDD with special emphasis on its uptake by nutrition. Arch. Toxicol. 71:1997;382-400
94. Krzyzanowski M., Quackenboss J.J., Lebowitz M.D. Relation of peak expiratory flow rates and symptoms to ambient ozone. Arch. Environ. Health. 47:1992;107-115
95. Kuhnz W., Jager-Roman E., Rating D., Deichl A., Kunze J., Helge H., Nau H. Carbamazepine and carbamazepine-10, 11-epoxide during pregnancy and postnatal period in epileptic mothers and their nursed infants: pharmacokinetics and clinical effects. Pediatr. Pharmacol. 3:1983;199-208
96. Kurata N., Nishimura Y., Iwase M., Fischer N.E., Tang B.K., Inaba T., Yasuhara H. Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 28:1998;1041-1047
97. LaCroix D., Sonnier M., Moncion A., Cheron G., Cresteil T. Expression of CYP3A in the human liver. Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem. 247:1997;625-634
98. Lam C.-W., Galen T.J., Boyd J.F., Pierson D.L. Mechanism of transport and distribution of organic solvents in blood. Toxicol. Appl. Pharmacol. 104:1990;117-129
99. Lecce J.G. Selective absorption of macromolecules into intestinal epithelium and blood by neonatal mice. J. Nutr. 102:1972;69-75
100. Lelo A., Miners J.O., Robson R.A., Birkett D.J. Quantitative assessment of caffeine partial clearances in man. Br. J. Clin. Pharmacol. 22:1986;183-186
101. Lerman J., Gregory G.A., Willis M.M., Eger E.I. Age and solubility of volatile anesthetics in blood. Anesthesiology. 61:1984;139-143
102. Levy G., Khanna N.N., Soda D.M., Tsuzuki O., Stern L. Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in raltion to plasma bilirubin concentration and D-glucaric acid excretion. Pediatrics. 55:1975;818-825
103. Lin Y.-S., Smith T.J., Kelsey K., Wypij D. Human physiologic factors in respiratory uptake of 1,3-butadiene. Environ. Health Perspect. 109:2001;921-926
104. Lorber M., Phillps L. Infant exposure to dioxin-like compounds in breast milk. Environ. Health Perspect. 110:2002;A325-A332
105. Mace K., Aguilar F., Wang J.-S., Vautravers P., Gomez-Lechon M., Gonzalez F.J., Groopman J., Harris C.C., Pfeifer A.M.A. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis. 18:1997;1291-1297
106. Martonen T.B., Musante C.J., Segal R.A., Schroeter J.D., Hwang D., Dolovich M.A., Burton R., Spencer R.M., Fleming J.S. Lung models: strengths and weaknesses. Respir. Care. 45:2000;712-736
107. Matsuda T., Imaoka S., Funae Y., Otori K., Fukushima S. Induction of CYP isoenzymes in various organs of rats by 3-methylcholanthrene or beta-naphthoflavone. Cancer Lett. 97:1995;137-143
108. Mayers D.J., Hindmarsh K.W., Sankaran K., Gorecki D.K., Kasian G.F. Chloral hydrate disposition following single-dose administration to critically ill neonates and children. Dev. Pharmacol. Ther. 16:1991;71-77
109. McCarver D.G., Hines R.N. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther. 300:2002;361-366
110. Miller R.P., Roberts R.J., Fischer L.J. Acetaminophen elimination kinetics in neonates, children, and adults. Clin. Pharmacol. Ther. 19:1976;284-294
111. Morselli P.L. Clinical pharmacology of the perinatal period and early infancy. Clin. Pharmacokinet. 17(Suppl. 1):1989;13-28
112. Mulhall A., deLouvois J., Hurley R. Chloramphenicol toxicity in neonates: its incidence and prevention. Br. Med. J. 287:1983;1424-1427
113. Murry D.J., Crom W.R., Reddick W.E., Bhargava R., Evans W.E. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab. Dispos. 23:1995;1110-1116
114. Nakajima T., Wang R.-S., Murayama N., Sato A. Three forms of trichloroethylene-metabolizing enzymes in rat liver induced by ethanol, phenobarbital, and 3-methylcholanthrene. Toxicol. Appl. Pharmacol. 102:1990;546-552
115. Nakamura H., Tanaka E., Ishikawa A., Fukao K., Tsuji K., Ohkawa H. Age-related changes in hepatic drug-oxidizing activity using trimethadione as a probe drug in humans. Hepatol. Res. 12:1998;85-92
116. National Research Council (NRC) Pesicides in the Diets of Infants and Children. 1993;National Academy Press, Washington, DC
117. Nedelcheva V., Gut I., Soucek P., Tichavska B., Tynkova L., Mraz J., Guengerich F.P., Ingelman-Sundberg M. Metabolism of benzene in human liver microsomes: individual variations in relation to CYP2E1 expression. Arch. Toxicol. 73:1999;33-40
118. Nemeth I., Boda D. Blood gluathione redox ratio as a parameter of oxidative stress in premature infants with IRDS. Free Radical Biol. Med. 16:1994;347-353
119. Nielsen P., Friis C., Gyrd-Hansen N., Kraul I. Disposition of parathion in neonatal and young pigs. Pharmacol. Toxicol. 69:1991;233-237
120. Oda Y., Aryal P., Terashita T., Gillam E.M., Guengerich F.P., Shimada T. Metabolic activation of heterocyclic amines and other procarcinogens in Salmonella typhimurium umu tester strains expressing human cytochrome P4501A1, 1A2, 1B1, 2C9, 2D6, 2E1, and 3A4 and human NADPH-P450 reductase and bacterial O-acetyltransferase. Mutat. Res. 492:2001;81-90
121. Ohmori S., Nakasa H., Asanome K., Kurose Y., Ishii I., Hosokawa M., Kitada M. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim. Biophys. Acta. 1380:1998;297-304
122. Pacifici G.M., Franchi M., Colizzi C., Giuliani L., Rane A. Glutathione S-transferase in humans: development and tissue distribution. Arch. Toxicol. 61:1988;265-269
123. Papp A., Nemeth I., Karg E., Papp E. Glutathione status in retinopathy of prematurity. Free Radical Biol. Med. 27:1999;738-743
124. Pariente-Khayat A., Pons G., Rey E., Richard M.-O., D'Athis P., Moran C., Badoual J., Olive G. Caffeine acetylator phenotyping during maturation in infants. Pediatr. Res. 29:1991;492-495
125. Pelekis M., Gephart L.A., Lerman S.E. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. Regul. Toxicol. Pharmacol. 33:2001;12-20
126. Pikkarainen P.H., Raiha N.C. Development of alcohol dehydrogenase activity in the human liver. Pediatr. Res. 1:1967;165-168
127. Pons G., Rey O., Carrier M.O., Moran R.C., Badoual J., Olive G. Maturation of AFMU excretion in infants. Fundam. Clin. Pharmacol. 3:1989;589-595
128. Price P., Chaisson C., Conolly R.B., Young J.S. A Project to Model Inter- and Intra-individual Variation in Physiological Factors used in PBPK Models of Humans. 2002;LINEA, Portland, ME. 58 pp.
129. Price K., Haddad S., Krishnan K. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ. Health, Part A. 66:2003;417-433
130. Pyonnonen S., Sillanpaa M., Frey H., Iisalo E. Carbamazepine and its 10,11-epoxide in children and adults with epilepsy. Eur. J. Clin. Pharmacol. 11:1977;129-133
131. Ratanasavanh D., Beaune P., Morel F., Flinois J.P., Guengerich F.P., Guillouzo A. Intralobular distribution and quantitation of cytochrome P-450 enzymes in human liver as a function of age. Hepatology. 13:1991;1142-1151
132. Rao H.V., Ginsberg G.L. A physiologically-based pharmacokinetic model assessment of methyl t-butyl ether in groundwater for a bathing and showering determination. Risk Anal. 17:1997;583-597
133. Reimche L.D., Sankaran K., Hindmarsh K.W., Kasian G.F., Gorecki D.K.J., Tan L. Chloral hydrate sedation in neonates and infants - Clinical and pharmacologic considerations. Dev. Pharmacol. Ther. 12:1989;57-64
134. Renwick A.G. Toxicokinetics in infants and children in relation to the ADI and TDI. Food Addit. Contam. 15:1998;17-35. (Suppl.)
135. Renwick A.G., Dorne J.L., Walton K. An analysis of the need for an additional uncertainty factor for infants and children. Regul. Toxicol. Pharmacol. 31:2000;286-296
136. Saunders N.R., Knott G.W., Dziegielewska K.M. Barriers in the immature brain. Cell. Mol. Neurobiol. 20:2000;29-40
137. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exper. Ther. 270:1994;414-423
138. Shimada T., Yamazaki H., Mimura M., Wakamiya N., Ueng Y.-F., Guengerich F.P., Inui Y. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs. Drug Metab. Dispos. 24:1996;515-522
139. Shimada T., Oda Y., Gillam E.M.J., Guengerich F.P., Inoue K. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and 1B1 alleleic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab. Dispos. 29:2001;1176-1182
140. Siegers C.P., Horn W., Younes M. Effect of phorone-induced glutathione depletion on the metabolism and hepatotoxicity of carbon tetrachloride and vinylidene chloride in rats. J. Appl. Toxicol. 5:1985;352-356
141. Sinjari T., Tornwall U., Darnerud P.O. Induction of 7-ethoxyresorufin-O- deethylase (EROD) activity in mice foetuses by the PCB-congener 3,3′,4,4′-tetrachlorobiphenyl. Xenobiotica. 23:1993;107-114
142. Slikker W. The role of metabolism in the testing of developmental toxicants. Regul. Toxicol. Pharmacol. 7:1987;390-413
143. Smith M., Hopkinson D.A., Harris H. Developmental changes and polymorphism in human alcohol dehydrogenase. Ann. Hum. Genet. 34:1971;251-271
144. Sonnier M., Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur. J. Biochem. 251:1998;893-898
145. Srivastava S.P., Das M., Seth P.K. Enhancement of lipid peroxidation in rat liver on acute exposure to styrene and acrylamide. A consequence of glutathione depletion. Chem.-Biol. Interact. 45:1983;373-380
146. Strange R.C., Howie A.F., Hume R., Matharoo B., Bell J., Hiley C., Jones P., Beckett G.J. The developmental expression of alpha-, mu- and pi-class glutathione S-transferases in human liver. Biochim. Biophys. Acta. 993:1989;186-190
147. Suter-Eichenberger R., Boelsterli U.A., Conscience-Egli M., Lichtensteiger W., Schlumpf M. CYP 450 enzyme induction by chronic oral musk xylene in adult and developing rats. Toxicol. Lett. 115:2000;73-87
148. Szorady I., Santa A., Veress I. Drug acetylator phenotypes in newborn infants. Biol. Res. Pregnancy. 8:1987;23-25
149. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J. Clin. Pharmacol. Ther. 23:1998;403-416
150. Tanaka E., Terada M., Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J. Clin. Pharmacol. Ther. 25:2000;165-175
151. Tang J., Cao Y., Rose R.L., Brimfield A.A., Dai D., Goldstein J.A., Hodgson E. Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab. Dispos. 29:2001;1201-1204
152. Teichberg S., Isolauri E., Wapnir R.A., Roberts B., Lifshitz F. Development of the neonatal rat small intestinal barrier to nonspecific maromolecular absorption: effect of early weaning to artificial diets. Pediatr. Res. 28:1990;31-37
153. Templin M.V., Stevens D.K., Stenner R.D., Bonate P.L., Tuman D., Bull R.J. Factors affecting species differences in the kinetics of metabolites of trichloroethylene. J. Toxicol. Environ. Health. 44:1995;435-447
154. Testai E., DeCurtis V., Gemma S., Fabrizi L., Gervasi P., Vittozzi L. The role of different cytochrome P450 isoforms in in vitro chloroform metabolism. J. Biochem. Toxicol. 11:1996;305-312
155. Their R., Pemble S.E., Kramer H., Taylor J.B., Guengerich F.P., Ketterer B. Human glutathione S-transferase T1-1 enhances mutagenicity of 1,2-dibromoethane, dibromomethane and 1,2,3,4-diepoxybutane in Salmonella typhimurium. Carcinogenesis. 17:1996;163-166
156. Thurlbeck W.M. Postnatal human lung growth. Thorax. 37:1982;564-571
157. Treyluyer J.M., Cheron G., Sonnier M., Cresteil T. Cytochrome P450 expression in sudden infant death syndrome. Biochem. Pharmacol. 52:1996;497-504
158. USEPA (1994a). Guidance Manual for the Integrated Exposure Uptake Biokinetic Model for Lead in Children. EPA 540-R-93-081; PB93-963510.
159. USEPA (1994b). Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry. EPA/600/8-90/066F.
160. USEPA (2000). Summary Report of the Technical Workshop on Issues Associatedwith Considering Developmental Changes in Behavior and Anatomy when Assessing Exposure to Children. Risk Assessment Forum, 10/31/2000.
161. USEPA (2000). Child-Specific Exposure Factors Handbook. External Review Draft, 6/2000. NCEA-W-0853.
162. Van Vleet T.R., Klein P.J., Couloumbe R.A. Metabolism and cytotoxicity of aflatoxin B1 in cytochrome P-450-expressing human lung cells. J. Toxicol. Environ. Health, Part A. 65:2002;853-867
163. Vasiliou V., Pappa A. Polymorphisms of human aldehyde dehydrogenase. Pharmacology. 61:2000;192-198
164. Vest M.F. The development of conjugation mechanisms and drug toxicity in the newborn. Biol. Neonate. 8:1965;258-266
165. Vieira I., Sonnier M., Cresteil T. Development expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur. J. Biochem. 238:1996;476-483
166. Vukavic T. Timing of the gut closure. Pediatr. Gastroenterol. Nutr. 3:1984;700-703
167. Waddell W.J., Marlowe C. Transfer of drugs across the placenta. Pharmacol. Ther. 14:1981;375-390
168. Walsh C.T. The influence of age on the gastrointestinal absorption of mercuric chloride and methyl mercury chloride in the rat. Environ. Res. 27:1982;412-420
169. Ward R.J., McPherson A.J.S., Chow C., Ealing J., Sherman D.I.N., Yoshida A., Peters T.J. Identification and characterization of alcohol-induced flushing in Caucasian subjects. Alcohol Alcohol. 29:1994;433-438
170. West J.R., Smith H.W., Chasis H. Glomerular filtration rate, effective renal blood flow, and maximal tubular excretory capacity in infancy. J. Pediatr. 32:1948;10-18
171. Wester R.C., Maibach H.I., Surinchak J., Bucks D.A.W. Predictability of in vitro diffusion systems. Effect of skin types and ages on percutaneous
172. Yokoyama A., Muramatsu T., Ohmori T., et al. Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis. 19:1998;1383-1387
173. Yoo S.D., Burgio D.E., McNamara P.J. Phenobarbital disposition in adult and neonatal rabbits. Pharm. Res. 11:1994;1204-1206
174. Young J.F., Branham W.S., Sheehan D.M., Baker M.E., Wosilait W.D., Luecke R.H. Physiological "constants" for PBPK models for pregnancy. J. Toxicol. Environ. Health. 52:1997;385-401
175. Zemlickis D., Klein J., Moselhy G., Koren G. Cisplatin protein binding in pregnancy and the neonatal period. Med. Pediatr. Oncol. 23:1994;476-479